Yipinhong Pharmaceutical Co Ltd Class A - Asset Resilience Ratio

Latest as of March 2026: 0.66%

Yipinhong Pharmaceutical Co Ltd Class A (300723) has an Asset Resilience Ratio of 0.66% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Yipinhong Pharmaceutical Co Ltd Class A to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥31.00 Million
≈ $4.54 Million USD Cash + Short-term Investments

Total Assets

CN¥4.70 Billion
≈ $687.40 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's Asset Resilience Ratio has changed over time. See 300723 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Yipinhong Pharmaceutical Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300723 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥31.00 Million 0.66%
Total Liquid Assets CN¥31.00 Million 0.66%

Asset Resilience Insights

  • Limited Liquidity: Yipinhong Pharmaceutical Co Ltd Class A maintains only 0.66% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Yipinhong Pharmaceutical Co Ltd Class A Industry Peers by Asset Resilience Ratio

Compare Yipinhong Pharmaceutical Co Ltd Class A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Yipinhong Pharmaceutical Co Ltd Class A (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Yipinhong Pharmaceutical Co Ltd Class A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.11% CN¥4.75 Million
≈ $694.52K
CN¥4.40 Billion
≈ $644.46 Million
-0.81pp
2023-12-31 0.92% CN¥40.44 Million
≈ $5.92 Million
CN¥4.41 Billion
≈ $644.63 Million
-0.84pp
2022-12-31 1.76% CN¥72.19 Million
≈ $10.56 Million
CN¥4.10 Billion
≈ $599.73 Million
+1.36pp
2021-12-31 0.41% CN¥15.03 Million
≈ $2.20 Million
CN¥3.70 Billion
≈ $542.07 Million
-0.20pp
2020-12-31 0.61% CN¥13.00 Million
≈ $1.90 Million
CN¥2.15 Billion
≈ $313.90 Million
-1.38pp
2019-12-31 1.98% CN¥35.60 Million
≈ $5.21 Million
CN¥1.79 Billion
≈ $262.64 Million
--
pp = percentage points

About Yipinhong Pharmaceutical Co Ltd Class A

SHE:300723 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.21 Billion
CN¥15.10 Billion CNY
Market Cap Rank
#5992 Global
#1243 in China
Share Price
CN¥33.42
Change (1 day)
+1.95%
52-Week Range
CN¥29.56 - CN¥80.53
All Time High
CN¥80.53
About

ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao'er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxia… Read more